Bio-Rad Laboratories Files 8-K on Financials and Operations

TL;DR

Bio-Rad dropped an 8-K detailing financials, operations, and exit costs. Check the exhibits for the juicy details.

AI Summary

Bio-Rad Laboratories, Inc. filed an 8-K on February 13, 2025, reporting on results of operations and financial condition as of February 7, 2025. The filing also covers cost associated with exit or disposal activities, other events, and financial statements and exhibits. Specific financial details or outcomes of these activities were not disclosed in this summary.

Why It Matters

This filing provides investors with updates on Bio-Rad's financial performance and operational activities, including any restructuring or disposal costs, which are crucial for assessing the company's current health and future prospects.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting on financial condition and operations, not indicating any immediate or significant adverse events.

Key Players & Entities

• BIO-RAD LABORATORIES, INC. (company) — Registrant
• February 7, 2025 (date) — Earliest event date
• February 13, 2025 (date) — Filing date
• 1000 Alfred Nobel Drive, Hercules, California 94547 (address) — Principal executive office address

FAQ

Key Financial Figures

• $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
• $45 million — lan we will incur between approximately $45 million and $50 million in total cost, which we
• $50 million — r between approximately $45 million and $50 million in total cost, which we anticipate will
• $30 million — ipate that we will record approximately $30 million to $35 million of the charges related t
• $35 million — ill record approximately $30 million to $35 million of the charges related to this restruct

Filing Documents

• bio-20250207.htm (8-K) — 40KB
• bio-8k2132025xex991.htm (EX-99.1) — 441KB
• bio-8k2132025xex992.htm (EX-99.2) — 11KB
• picture1a.jpg (GRAPHIC) — 2KB
• 0000012208-25-000004.txt ( ) — 692KB
• bio-20250207.xsd (EX-101.SCH) — 2KB
• bio-20250207_def.xml (EX-101.DEF) — 15KB
• bio-20250207_lab.xml (EX-101.LAB) — 27KB
• bio-20250207_pre.xml (EX-101.PRE) — 16KB
• bio-20250207_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

ITEM 2.02 Results of Operations and Financial Condition On February 13, 2025, Bio-Rad Laboratories, Inc. announced its financial results for the quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

05 Costs Associated with Exit or Disposal Activities

ITEM 2.05 Costs Associated with Exit or Disposal Activities. On February 7, 2025, Bio-Rad Laboratories, Inc. (the "Company") initiated a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in the United States and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain operations to lower cost locations. The restructuring plan is expected to eliminate a total of approximately 5% of our workforce. We anticipate the restructuring plan will be substantially completed by the end of fiscal year 2025. We estimate that as a result of this restructuring plan we will incur between approximately $45 million and $50 million in total cost, which we anticipate will consist primarily of one-time termination benefits to the affected employees, including cash severance payments, healthcare benefits, and related transition assistance. We anticipate that we will record approximately $30 million to $35 million of the charges related to this restructuring plan in the first quarter of fiscal year 2025 with the balance expected to be recorded by the end of fiscal year 2025. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional charges and future cash payments could occur in relation to the restructuring actions. Note Regarding Forward-Looking Statements Certain statements set forth in Item 2.05 above constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning the Company's expectations or estimates relating to the restructuring plan, including the anticipated workforce reduction, timing of completion of the restructuring plan, and timing and amounts of the charge to be recorded and cash expenditures to be made in connection with

01 Other Events

ITEM 8.01 Other Events. O n February 13, 2025, Bio-Rad Laboratories, Inc. (the "Company") issued a press release announcing that the Company had entered into a binding offer to purchase all equity interests in Stilla Technologies (a French corporation). A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits Exhibit Number Description 99.1 Press release of Bio-Rad Laboratories, Inc. dated February 1 3 , 202 5 99.2 Press release of Bio-Rad Laboratories, Inc. dated February 13, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: February 13, 2025 By: /s/ Roop K. Lakkaraju Roop K. Lakkaraju Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR